NCT04656535 2026-04-17
AB154 Combined With AB122 for Recurrent Glioblastoma
Yale University
Phase EARLY_PHASE1 Active not recruiting
Clinical Trials
3 trialsNCT05130177 2026-03-31
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
University of Pittsburgh
Phase 2 Active not recruiting
NCT07397611 2026-03-20
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
Dana-Farber Cancer Institute
Phase 2 Recruiting